Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2025-01-25 Earnings Release
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated January 25, 2025, announcing the unaudited financial results for the quarter and nine months ended December 31, 2024. It includes key consolidated financial highlights such as revenues, gross profit, EBITDA, PAT, and margins for Q3 FY25 compared to Q3 FY24. The document is titled as a 'Press Release' and contains summarized financial results and commentary from the Chairman. It does not contain full financial statements or detailed analysis typical of an Interim/Quarterly Report (IR), but rather the initial announcement of quarterly financial results. Therefore, it fits the definition of an Earnings Release (ER). The document length (6218 characters) and content support this classification rather than a full interim report or regulatory filing.
2025-01-25 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and is addressed to stock exchanges pursuant to SEBI regulations, indicating it is a formal investor communication. It contains detailed financial highlights for Q3 and 9M FY25, including revenue, EBITDA, PBT, PAT, segment revenue contributions, and business overview. The content is typical of a presentation prepared for investors to provide financial results, business strategy, and market position. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or a brief summary. Therefore, it fits the definition of an Investor Presentation (IP).
2025-01-24 English
Integrated Filing- Financial
Regulatory Filings
2025-01-24 English
Resignation
Regulatory Filings
2025-01-24 English
General Updates
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) providing details of Key Managerial Personnel (KMP) pursuant to Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is a disclosure about management personnel for compliance and materiality determination purposes. There is no financial data, no report or presentation, no voting results, no legal proceedings, no capital changes, and no earnings information. The content fits the category of Board/Management Information (MANG), which covers announcements of changes or details about the company's board or senior management.
2025-01-24 English
Change in Director(s)
Board/Management Information Classification · 100% confidence The document is an official communication dated January 24, 2025, addressed to stock exchanges (BSE and NSE) regarding the appointment of two individuals as Independent Directors of the company. It references compliance with SEBI Listing Regulations and provides detailed profiles of the appointees, their terms of appointment, and disclosures related to their independence and qualifications. The document does not contain financial data, earnings, or report content but is an announcement of changes in the company's board of directors. Therefore, it fits the category of Board/Management Information (MANG). The document length and content confirm it is not a brief announcement or a report publication notice but a formal filing about management changes.
2025-01-24 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.